Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin‐induced peripheral neuropathy in Taiwanese patients with colorectal cancer

Abstract

The purpose of this study was to evaluate the longitudinal incidence, severity, pattern of changes or predictors of oxaliplatin‐induced peripheral neuropathy (OXAIPN) in Taiwanese patients with colorectal cancer. A longitudinal repeated measures study design was employed, and 77 participants were recruited from the colorectal and oncology departments of two teaching medical centres in Taiwan. Physical examinations were performed, and self‐reports regarding adverse impacts of OXAIPN and quality of life were obtained at five time points throughout 12 cycles of chemotherapy (C/T). The incidence of OXAIPN increased with C/T cycles (31.1%–81.9%), and the upper limb numbness and cold sensitivity were most significant acute OXAIPN symptoms (29.9%–73.6%). Findings also documented significant increases in overall severity, symptom distress, interference and physical results associated with OXAIPN over the course of C/T. Predictors of OXAIPN severity varied by treatment cycle, including younger patient, higher cumulative dose of oxaliplatin, greater body surface area, receipt of chemotherapy in winter and the occurrence of OXAIPN during prior C/T cycles. The results from this study might help healthcare providers to recognise the symptom characteristics, degree of influences, trends and high‐risk group of OXAIPN, facilitating early evaluation and potential interventions to mitigate or prevent negative effects of OXAIPN on patients.

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

“…This remarkable variability still needs to be fully explained because different studies have failed to unequivocally indicate which might be the risk factors or the predictors for the final neurological outcome in each patient. Apart from cumulative dose, which is clearly associated with more severe neurotoxicity, several other apparently obvious risk factors for peripheral nerve damage failed to demonstrate consistent results in different studies . This is the case for diabetes, age, previous chemotherapy, while other risk factors less commonly associated to increased incidence of peripheral neuropathies, such as body mass index and smoking, were occasionally reported.…”

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

“…The summed scores of each subscale and the overall CIPN scale are converted into standardized scores ranging from 0 to 100, with higher scores representing more CIPN–related symptom distress. The scale was translated into Chinese, and previous cancer-related studies reported satisfactory psychometric properties for the EORTC QLQ–CIPN20 [ 18 , 21 ]. The EORTC QLQ–CIPN20 has been demonstrated to be reliable in a cancer-related study [ 29 ].…”

“…Although previous studies have explored these issues, most research has focused on patients with colorectal cancer [ 18 , 19 , 20 ], breast cancer [ 21 ], or those in Western countries [ 22 , 23 , 24 ]; or on other chemotherapy regimens such as taxane [ 22 , 23 ], paclitaxel [ 23 , 24 ], or carboplatin [ 23 , 24 ]. Clinical observation indicates that LC patients treated with platinum-based regimens report CIPN-related symptoms that affect daily function and QoL, and insufficient attention has been devoted to this important topic.…”

High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study

“…These findings are consistent with those of previous research showing that numbness/tingling was associated with functional impairment and reduced QoL, [68,154,216,217] which interfered with daily activities [102] and reduced enjoyment of life. [218] Given the lack of effective treatment for numbness/tingling, it is important to assess this symptom and its severity systematically and to modify the chemotherapy dose when needed (dose limitation). [208,219]…”